of general laboratory examinations were listed in Table 1 . Urine and stool were normal. The sedimentation of erythrocytes was delayed. Liver function tests , serum electrolytes and serum lipids were all within normal limits . Peripheral blood was normal, and Congo-red index was also normal. Results of examinations on clotting factors were shown in Table 2 . Bleed ing time was prolonged over 15 minutes, and the blood did not completely clot , since the whole blood clotting time, recalcification time , partial thromboplastin time, one stage prothrombin time, thrombin time , and 'r' of thromboelastogram (TEG) were all infinite. Capillary fragility was somewhat reduced in both positive and negative pressure methods. Thromboplastin generation test (TGT) revealed that plasma, serum and platelets were normal . Prothrombin time after addition of fibrinogen, and activities of Factors V, VII and VIII were normal . Circulating anticoagulant was not recognized. Fibrinogen content was undeterminable since fibrin clot was not produced by the tyrosine method . No amplitudes were produced in TEG with the patient's blood alone, and no changes were seen when the patient's blood was added with bovine fibrinogen in a concentration up to 50mg/100ml, but a slight amplitude was noted when the patient's blood was added with bovine fibrinogen in a concentration over 75mg/100ml . Therefore, the critical concentration of fibrinogen to be demonstrated using TEG may be i n the range of 50 to 75mg/100ml. Though the presence of strong circulating anticoagulant (6) no precipitation was seen between the patient's plasma and antiserum, although a definite precipitation zone was noted between normal control plasma and antiserum in 48 hours' immuno-electrophoresis, as shown in Fig. 2 . A thin precipitation zone appeared around the patient's plasma in 72 hours, but this was considered to be the precipitation zone between normal control plasma and antiserum on the other side, because the precipitation zone approached to the normal control plasma with the lapse of time and increase in concentration of antiserum. Furthermore, no precipitation occurred between antiserum and the patient's plasma in Ouchter lony's method. These results indicate that fibrinogen is not present in our patient's plasma at the present time.
Fibrinolytic activities were evaluated by means of the fibrin plate method (Table 5 ). Since no lysis was seen with plasma, serum and euglobulin, free plas min was not recognized to be present. Addition of euglobulin and SK, however, caused lysis of 145.6mm2 in the standard plate, and 101.4mm2 in the heated plate as the average of 7 examinations. These were both significantly lower than the normal. Antiplasmin also seemed to be lower than the normal.
Four grams of human fibrinogen were intravenously administered and the turnover time was examined. Fibrinogen content was 138mg/100ml, highest in 30-60 minutes after the administration, and the half time was 3.2 days (Fig. 3) . Furthermore, blood fibrinolytic activities were examined at the sane time by means of the fibrin plate method (Fig. 4) . Activities of blood plasmin were intensified as soon as fibrinogen was administered, but returned to the original level with dis appearance of blood fibrinogen. Since the activities of plasminogen in transfused fibrinogen were not excluded in the curve of solid line in Fig. 4 , the actual changes in fibrinolytic activities of the patient's blood would be better represented by the dotted line in the lower part of the figure, which was obtained after calibration of plasminogen activities due to exogenous fibrinogen. After all, plasminogen was activated by fibrinogen administration, and it was consumed and finally returned to the initial level with disappearance of exogenous fibrinogen. The genealogy of the patient was shown in Fig. 5 . The parents were in cousinship. Results of family examinations are shown in Table 6 . Partial thromboplastin time, one stage prothrombin time and fibrinolytic activities in the fibrin plate method were all normal; 6 of 8 members (parents , brother, sister, aunt and grandmother of paternal side) were found to have hypofibrinogenemia . Therefore, the disease appears almost equally in both sexes, the male being slightly predominant, whereas 4 of 14 cases were male and 10 female in our series, Age. Age of the onset was shown in Table 8 . Eleven cases developed bleeding immediately after birth until the 10th day, and only one case developed bleeding in the third week of life. Konoshita et al. 6 described a case which had no episode of bleeding until 5 years of age, when gingival and subcutaneous bleeding occurred. According to Bommer et al.,17 21 out of 27 cases had bleeding within 14 days of birth, 2 within a year, 3 from 1 to 5 years, and 1 from 5 to 10 years.
Age at the time of examination varied in our series: 1 was a new-born infant, 5 from 1 to 5 years of age, 4 from 6 to 10 years of age, 4 from 11 to 15 years of age. Bommer et al.17 also reported that 15 cases (27%) developed the symptom between 1 and 5 years of age, followed by 13 cases (22%) from 10 to 20 years of age, 9 cases (16%) from 5 to 10 years of age, 8 cases (15%) of new-born infant, and 6 cases (11%) in the first year of life.
Heredity and hemorrhagic diathes in siblings.
Congential afibrinogenemia appears in both sexes and often in a child or grandchild of intermarriage. Hemor rhagic diathesis is often observed in their siblings. This disorder is of recessive heredity but is said to be not sex-linked. Of 12 cases in our series, in which hereditary relations were well described, intermarriage was noted in parents of 5 cases. Episodes of hemorrhagic diathesis were observed in siblings of 7 cases. In 43 of 55 cases of Bommer et al.,17 intermarriage was found in 24 cases (56%), and episodes of hemorrhagic diathesis were recognized in siblings of 25 cases (47%).
Bleeding site. Umbilical bleeding occurred in 12 of 14 cases in our series, and subcutaneous bleeding due to trauma was seen only in one case. Past history of umbilical bleeding was found in 12 cases, subcutaneous bleeding or hematoma due to trauma in 10 cases, nasal and gingival bleeding in 3 cases, and joint bleeding due to trauma in 2 cases. In addition, hematemesis and melena were seen in 1 case each. That umbilical bleeding occurred in the majority of cases was noted also in the statistical studies of Boimmer et al. 17 Table 9 . In our series, bleeding time was within 5 mintues in 6 cases and over 10 minutes in 8 cases. Whole blood clotting time was infinite in all. Platelet count was normal in all but one case with platelets under 100,000. The count was 100,000-200,000 in 7 cases and over 200,000 in 6 cases. Capillary fragility was normal in the positive pressure method in 8 of 11 cases and reduced in 3. In the negative pressure method, it was normal in 6 of 9 cases. One-stage prothrombin time was infinite in all, and that of two-stage was normal in all (5 cases). Thrombotest was normal in all (3 cases), while recalcification time (11 cases), partial thromboplastin time (3 cases), and 'r' of TEG (3 cases) were infinite. All of these data indicate complete defect of blood coagulation.
Thromboplastin screening test (3 cases) was normal; TGT (13 cases) showed normal activities in barium sulfate-treated plasma, serum and platelets; Factor V (10 cases), Factor VII (7 cases), Factor VIII (5 cases), Factor IX (2 cases), Factor X (2 cases), contact factor (2 cases) and Factor XIII (1 case) were all normal.
The circulating anticoagulant (10 cases) was not present; serum calcium (6 cases) was normal; antithrombin (2 cases) was not found, and heparinoid (1 case) was negative. The functions of platelet were evaluated in detail by Yoshida and Fukui7 and Kamisue et al.14 Platelet factors 1 and 2 were 100% and 30 seconds, respectively, in a case reported by Yoshida and Fukui,7 and platelet factor 3 (4 cases) was within normal limits, being 85-100%,. it is naturally assumed that platelet functions, especially agglutination and adhesiveness, play an important role in the blood clotting mechanism in congenital afibrinogenemia (Table 10) .
Agglutination was examined in 6 cases and was found to be normal except for one case of Shimada et al., 1 and adhesiveness was found to be normal in a case of Kamisue et al. 14 Gugler et al.20 have mentioned that the platelets in congenital afibrinogenemia do not show immunological evidence for the presence of fibrinogen on the surface and do not undergo morpho logical changes within the blood by contact with a glass surface, but the addition of fibrinogen causes changes of adhesion, agglutination, formation of pseudopods, and extension as in normal blood. It is also said that the addition of thrombin to detectable concentration of fibrinogen by means of thrombin time using human fibrinogen solution and diluted normal human plasma. Since fibrin net was definitely recognized at a fibrinogen concentration of 6mg/100ml, or 3mg/100 ml in some cases, it is concluded that fibrinogen is detected when it exceeds 5-6 mg/100ml. concentration of fibrinogen by the immunoprecipitation method16 and found that fibrinogen in a concentration of 0.6mg/100ml was detectable. Kawai et al. 9 have mentioned that diffusion method in agar-agar gel of Oudin is the most sensitive and fibrinogen is quantitatively detected at a level of 0.3mg/100ml. According to our experience, the concentration, over which fibrin clot is produced by thrombin, is approximately 25mg/100ml. Even below that concentration fibrin net is formed, but fibrin is hardly detected at a concentration below 5mg/100ml. Therefore, it seems that some cases of hypofibrinogenemia besides the above mentioned ones might have been included in cases of afibrinogenemia before the development of the immunological method. The lowest detectable limit of the current immunological According to the classification of Kawai et al.,9 cases without any noticeable fibrin clot in the clotting method are classified into the group of afibrinogenemia in a broader sense when an immunological trace of fibrinogen is demonstrated, the disease is regarded as severe hypofibrinogenemia, and when fibrinogen is negative even by immunological methods, afibrinogenemia in a strict sense is diagnosed. It seems, therefore, that afibrinogenemia in a true sense is extremely rare.
There are many reports in which accelerated turnover of fibrinogen is regarded The values are essentially the same in this country, and the half time in congenital afibrinogenemia is considered to be normal.
Accelerated fibrinolytic activities are considered to be one of the pathogenic factors of afibrinogenemia. The fibrinolytic activity was examined on 6 cases in our country besides our case . It was found that the lysis did not occur by euglobulin alone, but occurred by addition of SK , and antiplasmin was normal in a case of Shimada et al. 5 The fibrinolytic activity in Konoshita et al.'s case6 was presumably at the lowest limit of normal or slightly lower than the normal . Euglobulin lysis time was normal in cases of Nakamura et al .12 and of Kamisue et al.14 The lysis time was 7 days and consequently normal by Ratnof's method in Nakamura's case.12 It was over 24 hours by Miale's method in Kawai's9 and Morita's cases,3 and was considered to be slightly lowered in the former and to be normal in the latter. Yoshida and Fukui7 reported that no clot was produced by the Macfarlane method and the result was of ambiguous meaning . In 2 cases of Niimi4 and Ogawa and Shiroiwa ,8 no definite fibrinolysis was noted, but they did not describe the methods used. Of 12 cases , in which the fibrinolytic activity was determined except for Yoshida and Fukui's case ,7 11 showed normal fibrinolysis except for one ease. We have determined the fibrinolytic activities of our case on 7 occasions using the fibrin plate method and found that euglobulin itself did not dissolve in both standard and heated plates , but dissolved by addition of SK. The mean values were 145.6mm2 in the standard plate and 101 .4mm2 in the heated plate; these were definitely lower than the normal values of 310mm2 and 160mm2. Antiplasmin was also slightly lower in 2 determinations . Soulier et al., 33 Astrup and van Creveld,32 Bommer et al . 17 and de Vries et al. 34 reported that no spontaneous lysis occurred but normal fibrinolysis was noted by addi tion of SK, and plasminogen was normal . Neither accelerated fibrinolysis enough to cause afibrinogenemia, nor definitely decreased fibrinolysis as seen in our case has hitherto been reported . In general, when acceleration of fibrinolysis attains a certain extent, it may lead to a dangerous major bleeding in conge nital afibrinogenemia even in the absence of strong fibrinolytic activities enough to cause the condition, in view of a significant clotting defect , since plasmin dissolves not only fibrin or fibrinogen, but also other clotting factors such as prothrombin , F actor VIII, etc. In all cases reported up to date , there is none having accelerat ed fibrinolysis. From the standpoint of homeostasis in the living organism , decreased fibrinolysis is rather beneficial for congenital deficiency of fibrinogen , which is the chief substrate for the fibrinolytic enzyme system . According to the study on 56 cases by Bommer et al.,17 the longest survivor is Risak's case35 of a 41-year-old patient, whose fibrinogen content is said to be 18mg/100ml, and the disease seems to be hypofibrinogenemia rather than afibrinogenemia in a strict sense. With the exception of this case, there are no survivors over 30 years of age and only 9 survivors (16%) over 15 years. In our series, there are 4 cases of over 11 years of age, 4 from 6 to 10 years, and 6 from 0 to 5 years. Our own case is the only one of over 15 years of age. This implies that the prognosis of this disease is serious on account of dangerous major bleeding from insignificant causes. It is presumably related to the above-mentioned decreased fibrinolytic activity in our case, in which umbilical bleeding on the 8th day of life stopped without transfusion. Almost normal school life has been continued until today without any episode of life-threatening bleeding. Though there are no reports on the effect of transfused fibrinogen on fibrinolytic activities in congenital afibrinogenemia, plasminogen is temporarily consumed by transfused fibrinogen and returned to the normal level with turnover of fibrinogen. There is no reactive acceleration in fibrinolysis.
As the etiological causes of afibrinogenemia, the following factors are taken into consideration: (1) acceleration of fibrinogen turnover, (2) acceleration in fibrinolysis, and (3) decrease in fibrinogen synthesis. Since no acceleration of fibrinogen turnover or fibrinolysis has been confirmed as already mentioned, decrease in fibrinogen synthesis must be a cause of afibrinogenemia. Although there are many reports as to where fibrinogen is produced, no consensus of opinions has been obtained yet. The theory that fibrinogen is produced in the liver is now prevailing based on animal experiments of hepatectomy. McMaster and Drury36 replaced the blood of hepatectomized rabbits and of control rabbits with defibrinat ed blood, and found that fibrinogen was not all produced in the former, whereas fibrinogen content in the latter attained 90% of the normal value, and concluded that fibrinogen was produced only in the liver. In addition, Rosenthal et al. 37 reported that fibrinogen completely disappeared from the blood of mammarians 14-15 hours after hepatectomy, and Fleischacker38 mentioned that fibrinogen was contained in the maximum concentration in the blood from the hepatic vein. Recently, from irrigation experiment with an extirpated liver, Adelson et al. 28 has confirmed that fibrinogen is produced in the liver, and determined using a radioiso tope that fibrinogen production in the liver is 1.5-5.0g/day. They found further that the liver was able to produce more fibrinogen when fibrinogen concentration in the irrigated fluid was low than when it was high, namely, the liver was able to adjust fibrinogen production according to the concentration of fibrinogen in the blood. Straub,39 using tissue culture, radioisotope and immunofluorescence technics demonstrated that fibrinogen was produced in the liver in vitro. Barnhart and Anderson 40 and Forman and Barnhart41 using immunofluorescence also showed that fibrinogen was produced in the microsome or ribosome of the liver cells. From these experimental results and clinical observations that fibrinogen is decreased in severe liver diseases, and after administration of hepatic toxins, there is no doubt that the liver is the most important organ to produce fibrinogen. On the other hand, unless the liver function disturbances are severe, decrease in fibrinogen hardly occurs, and Eppinger42 has reported that hypofibrinogenemia does not frequently occur even in hepatectomized dogs. The findings suggest that there is possibly a site producing fibrinogen other than the liver. Henderson et al. 43 thought that the production of fibrinogen was related to all the reticuloendothelial system, including the liver and bone marrow. Bommer et al.17 acknowledged the possibility of fibrinogen production outside the liver, since fibrinogen was produced by stimulating the reticuloendothelial system of hepatectomized animals. From these facts, Bommer et al.17 thought that fibrinogen was produced in the reticulo endothelial system of the liver, spleen and bone marrow, and antiplasmin is produced at the same time in the liver in order to preserve fibrinogen produced in the liver. Namely, it may be concluded that most of fibrinogen is produced in the microsome or ribosome of the liver cells and, in addition, in the reticuloendo thelial system of the spleen and bone marrow .
It has been reported that the histological findings and function tests of the liver are not abnormal in this disroder, but it is assumed that the fine structure and functions of the liver and other fibrinogen-producing cells may have some abnormalities.
Plasma fibrinogen content in parents and siblings was tabulated in Table 12 . Of 6 well documented cases, low fibrinogen content was seen in 2 of 4 fathers , in 2 of 6 mothers, in 1 elder brother and 2 other silbings . Of 6 cases, 3 (50%) had hypofibrinogenemia or afibrinogenemia in their siblings . According to Bommer et al.,17 8 (58%) of 19 well documented cases had patients with hypofibrinogenemia or afibrinogenemia in their siblings. Though this tendency is quite similar in our series, there is no case having hypofibrinogenemia in parents as in our case .
A treatment is required when bleeding occurs or in cases of surgery . The treatment consists of transfusions of blood , plasma or fibrinogen fraction, the last of which is especially effective. The threshold value of fibrinogen concentra tion for stopping bleeding has never been evaluated in detail on patients in our country, and it is quite different among the reports from foreign countries .
Jurgens and Trautwein45 reported it to be 120-150mg/100ml , Risak35 100 mg/100ml and Macfarlane44 60mg/100ml . There is further an opinion that the threshold value is influenced by other clotting factors . Blood transfusion is more effective in this disease than in hemophilia , because the half time of transfused human fibrinogen is longer than Factor VIII , which is deficient in hemophilia. Caution is needed, since repeated administrations of fibrinogen may produce the antibody against it.
With the exception of two cases, Morita and Kagami's case3 of a now 14 year -old patient and Shimada et al.'s mortal case of nose bleeding , there are no reports on the prognosis of the disease in our country . Bommer et al. 17 reported that 8 of 55 cases died of bleeding. However, it is now considered that with the advancement 
